CAMBRIDGE, Mass. & OSAKA, Japan -- -- Takeda Pharmaceutical Company Limited today announced that the randomized, double-blind, placebo-controlled TOURMALINE-MM1 pivotal Phase 3 trial evaluating the safety and efficacy of ixazomib, the first oral proteasome inhibitor, conducted in patients with relapsed or refractory multiple myeloma achieved its primary endpoint of improving progression-free survival at the first pre-specified interim analysis.
http://ift.tt/1Aet0Yb
http://ift.tt/1Aet0Yb
No comments:
Post a Comment